Monitoring minimal residual disease after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) confirmed by biopsy
- Your cancer stage is I, II, or IIIA and it was considered resectable
- You had complete surgical removal of the tumor with clear margins (no R1 or R2)
- You are at least 18 years old and can sign consent
- Your lung cancer is not mixed with small cell lung cancer
- You have not had another cancer in the past 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This study checks if people with early-stage non-small cell lung cancer can safely skip chemotherapy or radiation after surgery when repeated blood tests show no sign of cancer left. You would only be watched with regular scans and blood tests to make sure the cancer doesn't come back.
This trial is studying a blood test that looks for tiny bits of cancer DNA after surgery for stage III colorectal cancer. The goal is to find out how well this test can predict whether cancer might come back, so you and your doctor can make better treatment decisions.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study looks at whether checking for tiny traces of cancer left in the blood (called minimal residual disease) after treatment can tell if lung cancer might come back. It may help doctors decide how often to monitor patients in the future.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.